Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma

Keyphrases

• Adverse Effect Profile 14%
• Adverse Events 14%
• Agent Behavior 14%
• Agent Interaction Protocols 14%
• Canine 100%
• Chemotherapy Combinations 14%
• Clinical Significance 14%
• Combination Chemotherapy 14%
• Complete Response 42%
• Doxorubicin 100%
• Financial Resources 14%
• Gastrointestinal 14%
• Guanine 14%
• Hematologic 14%
• Lymphoma 28%
• Mechanism of Action 14%
• Multi-agent 14%
• Multicentric Lymphoma 100%
• Nave 100%
• Nucleoside Analogues 14%
• Overall Response Rate 14%
• Partial Response 14%
• Previously Untreated 14%
• Prodrug 14%
• Progression-free Interval 14%
• Prospective Clinical Trial 14%
• Pulmonary Fibrosis 14%
• Remission 14%
• Self-limiting 28%
• Time Resources 14%
• Tolerability 100%
• Treatment Standards 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 28%
• Chemotherapy 28%
• Clinical Trial 14%
• Dermatological Agent 14%
• Doxorubicin 100%
• Guanine 14%
• Lung Fibrosis 14%
• Prodrug 14%
• Progression Free Survival 14%
• Rabacfosadine 100%
• Remission 14%
• Tolerability 100%

Veterinary Science and Veterinary Medicine

• Canine 100%
• Dog 100%
• Doxorubicin 100%